In addition, Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist Biopharma to license additional antibodies for up to five targets over the next four years.
Twist Bioscience granted a license to Revelar for the exclusive development of an antibody lead along with a series of back up compounds for the potential treatment of SARS-CoV-2.
Twist may receive success-based milestone payments totaling over USD 100m for the achievement of key development, regulatory and commercial milestones, as well as mid-single digit royalties on any future net sales.
In addition, Revelar may license up to five additional antibody therapeutics over the next four years, each of which will be subject to additional upfront, milestone and royalty payments to Twist.
Twist has committed to invest up to USD 10m in seed funding based on Revelar's progress in the development of the lead antibody and the potential licensing of additional antibody therapeutics.
In exchange for its cash investment, the antibody, and its back-up compounds, Twist received significant minority ownership in Revelar.
Revelar's executive leadership team includes Glenn Marina, Kevin Malobisky (chief regulatory and quality officer), Laurence Smith (CFO and general counsel), and Rodrigo Mesquita (vice president of operations and project management).
The board will be comprised of David Scheer (chairman), Paul Fonteyne, Brett Giroir, Emily Leproust (Twist Bioscience's CEO and co-founder) and Patrick Finn (Twist Bioscience's chief commercial officer).
Revelar Biotherapeutics is a biopharmaceutical company focused on developing and commercializing breakthrough therapeutic antibody products that address critical unmet patient needs for COVID-19 and other therapeutic areas.
The management team of Revelar Biotherapeutics has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations with leading global pharmaceutical companies.
The company's therapeutic areas of interest include oncology, autoimmune disorders, and infectious diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial